Skip to main content

Displaying 2173 - 2184 of 4528

The Outperformers

August 4, 2022

We debuted a new scan recently- The Outperformers.

The Outperformers is our newest scan that pinpoints the very best stocks in the market. It’s the fastest, easiest way to find quality names that are primed for major moves.

The goal is that as the market rally progresses, the sector rotation within the market will reflect in this scan. So while our Top/Down Analysis helps us with the broader view of the market, this Bottom/Up scan makes sure that we catch the slightest change in sentiment.

Insiders Are Hot for This Summer Rally

August 4, 2022

Insiders are finally buying into the summer rally. We haven’t seen this much action on our Hot List in months!

The largest insider transaction on today’s list is a Form 4 filing by the Chairman and CEO of American Assets Trust $AAT, with a roughly $1 million purchase.

Highest. Close. Ever.

August 3, 2022

There she goes!

Apple just went out at new all-time highs relative to the S&P500.

I think about it like this: Should we expect Tech stocks to underperform if the biggest one of them all is making new all-time relative highs?

All Star Charts Premium, 2 to 100 Club

2 to 100 Club (08-03-2022)

August 3, 2022

From the desk of Steve Strazza @Sstrazza

Welcome to the 2 to 100 Club.

As many of you know, something we've been working on internally is using various bottom-up tools and scans to complement our top-down approach. It's really been working for us!

One way we're doing this is by identifying the strongest growth stocks as they climb the market-cap ladder from small- to mid- to large- and, ultimately, to mega-cap status (over $200B).

Once they graduate from small-cap to mid-cap status (over $2B), they come on our radar. Likewise, when they surpass the roughly $30B mark, they roll off our list.

But the scan doesn't just end there.

We only want to look at the strongest growth industries in the market, as that is typically where these potential 50-baggers come from.

August Strategy Session: 3 Key Takeaways

August 3, 2022

From the Desk of Steve Strazza @Sstrazza

We held our August Monthly Strategy Session Monday night. Premium Members can access and re-watch it here.

Non-members can get a quick recap of the call simply by reading this post each month.

By focusing on long-term, monthly charts, the idea is to take a step back and put things into the context of their structural trends.

This is easily one of our most valuable exercises as it forces us to put aside the day-to-day noise and simply examine markets from a “big-picture” point of view.

With that as our backdrop, let’s dive right in and discuss three of the most important charts and/or themes from this month’s call.

Chart of the Day: "The" Facebook

August 3, 2022

When the worst stocks on the planet can't go down any more, that's usually good information.

We saw a lot of Small-cap Growth, Arkk Funds, Biotech, Chinese Internet and many of those other "Growthy" areas bottom out this Spring, and some of the last ones in June.

At the Mega-cap level, nothing caused more shareholder wealth destruction than Facebook, down 60% from its highs less than a year ago.

But look where prices stopped falling:

The Game is Won or Lost in the Trenches

August 3, 2022

New Bull Market or just a Bear Market Rally?

That's the question I keep seeing.

And it's a fair one to ask.

Thanks to everyone who made it live last night for our Monthly Charts Strategy Session.

With a few breadth thrusts in recent weeks, and a little preview of what a weaker dollar could do to this market, we had plenty to talk about.

This question included: New Bull or Mean Reversion in a Bear?

I think the S&P500 tells an interesting story. You've got that massive top that formed throughout the past year, completing with a break of support this Spring.

And after further selling, the bounce has brought it back all the way to the neckline. These are the "trenches":

Insiders Are Buying LXRX

August 2, 2022

The largest insider transaction on today's list is a Form 4 filing by Artal Group, which reported a purchase of roughly $40.4 million in Lexicon Pharmaceuticals $LXRX.

Artal Group now owns 83,835,950 LXRX shares, representing a roughly 47.5% ownership stake.